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Abstract
The field of medical systems biology aims to advance understanding of molecular mechanisms that drive disease
progression and to translate this knowledge into therapies to effectively treat diseases. A challenging task is the
investigation of long-term effects of a (pharmacological) treatment, to establish its applicability and to identify potential
side effects. We present a new modeling approach, called Analysis of Dynamic Adaptations in Parameter Trajectories
(ADAPT), to analyze the long-term effects of a pharmacological intervention. A concept of time-dependent evolution of
model parameters is introduced to study the dynamics of molecular adaptations. The progression of these adaptations is
predicted by identifying necessary dynamic changes in the model parameters to describe the transition between
experimental data obtained during different stages of the treatment. The trajectories provide insight in the affected
underlying biological systems and identify the molecular events that should be studied in more detail to unravel the
mechanistic basis of treatment outcome. Modulating effects caused by interactions with the proteome and transcriptome
levels, which are often less well understood, can be captured by the time-dependent descriptions of the parameters. ADAPT
was employed to identify metabolic adaptations induced upon pharmacological activation of the liver X receptor (LXR), a
potential drug target to treat or prevent atherosclerosis. The trajectories were investigated to study the cascade of
adaptations. This provided a counter-intuitive insight concerning the function of scavenger receptor class B1 (SR-B1), a
receptor that facilitates the hepatic uptake of cholesterol. Although activation of LXR promotes cholesterol efflux and
-excretion, our computational analysis showed that the hepatic capacity to clear cholesterol was reduced upon prolonged
treatment. This prediction was confirmed experimentally by immunoblotting measurements of SR-B1 in hepatic
membranes. Next to the identification of potential unwanted side effects, we demonstrate how ADAPT can be used to
design new target interventions to prevent these.
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Introduction
A central aim of medical systems biology is the development of
computational models and techniques to study molecular mecha-
nisms that drive disease progression [1–13]. One potential
contribution of computational modeling is to assess the effectiveness
of pharmacological interventions to treat progressive diseases, e.g.,
Type 2 Diabetes and cardiovascular disease. A complicating factor
to simulate and predict the effects of these interventions is the
multiscale nature of the affected biological systems. The kinetic
computational models in biology are typically constructed to
simulate processes at a single timescale, usually capturing short-
term dynamics ranging from seconds to hours [14–19]. On the other
hand, pharmacological interventions usually affect multiple process-
es that operate at different timescales, which in turn range over an
extended time frame. A challenging but particularly relevant task is
the investigation of long-term effects of a pharmacological treatment
to determine its applicability and to identify potential side effects.
Formulating mathematical descriptions of these effects is further-
more complicated by the lack of sufficient information of the
underlying network structure and interaction mechanisms. An
example is the study of pharmacological treatments associated with
metabolic diseases [20,21]. The acquired experimental data
predominantly concern changes in plasma and tissue metabolite
concentrations during one or more stages of the treatment.
Conversely, it is less well understood to what extent the actual
metabolite fluxes change in time and how corresponding processes
are modulated by the treatment via interactions with the proteome
and transcriptome. As a consequence, in many cases insufficient
information is available to explicitly model the interaction mecha-
nisms that modulate the metabolic processes. The lack of
mechanistic descriptions of the modulating interactions in a
mathematical model, referred to as undermodeling [22], forms a
serious complication when studying the effects of a pharmacological
treatment by means of computational analyses.
In the present paper we propose a computational approach that
overcomes the aforementioned issues. The approach, called
Analysis of Dynamic Adaptations in Parameter Trajectories
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(ADAPT), employs mathematical modeling to predict the long-
term effects of a pharmacological intervention. We introduce a
concept of time-dependent descriptions of model parameters to
study the dynamics of molecular adaptations, making use of
experimental data obtained during different stages of an interven-
tion. These model parameters typically represent reaction rate
constants (linked to mass action or Michaelis-Menten kinetics), but
could be any other quantity expressible in a mathematical model.
The progression of adaptations is predicted by identifying
necessary dynamic changes in the model parameters to describe
the transition between experimental data obtained during different
stages of the treatment. The obtained dynamic trajectories of
model parameters, as well as metabolite concentrations and -
fluxes, are constrained by the network topology and kinetic
equations of the molecular processes. As such, our method exploits
and integrates the merits from constrained-based modeling
approaches (e.g., Flux Balance Analysis) and kinetic modeling.
ADAPT is therefore particularly useful to study biological systems
from which the network topology is relatively well known, such as
the mass fluxes in metabolic pathways. The modulating effects on
these pathways via interactions with the proteome and transcrip-
tome, which are less well understood, can be captured by the time-
dependent descriptions of the parameters. Hence, as will be shown
here, an advantage of ADAPT is that pathway adaptations can be
described without the necessity to develop detailed kinetic models
of the modulating mechanisms. Moreover, it could provide a
means to capture the effects of complex phenomena such as cell
differentiation, developmental changes, and aging, that may
contribute to the progression of long-term adaptations. The
approach originates from our previous work in which computa-
tional modeling was used to identify necessary differences in
parameters to describe how one phenotype could be evolved from
another [1]. While the latter study aimed to explore steady-state
differences between two experimentally observed phenotypes, the
present study focused on the identification of dynamic adaptations
induced by a treatment intervention.
Relevant applications of ADAPT are the investigation of
metabolic pathways in relation to progressive diseases such as
Type 2 Diabetes and cardiovascular disease. Dyslipidemia is an
important risk factor for these diseases, and recognized markers
such as plasma triglycerides, LDL- and HDL-cholesterol, are used
in clinical settings to assess disease risk and status. However, the
underlying molecular mechanisms inducing adaptations in lipid
metabolism are not fully understood, complicating the develop-
ment of effective treatments. In the present study, ADAPT was
applied to a model of mouse hepatic lipid and plasma lipoprotein
metabolism to identify which metabolic adaptations are induced
upon pharmacological treatment of mice by liver X receptor
(LXR) agonist T0901317. The family of liver X receptors, LXRa
and LXRb, plays a central role in the control of cellular lipid and
sterol metabolism. Activation of LXRs by pharmacological
agonists promotes the cellular efflux, transport, and excretion of
cholesterol from the body, hereby reducing atherosclerotic plaques
in rodents [23]. Therefore, LXRs are considered as potential drug
targets to treat or prevent atherosclerosis [24–26]. However,
pharmacological activation of LXR also induces the accumulation
of hepatic triglycerides and promotes the secretion of enlarged
very-low-density-lipoprotein (VLDL) particles, which complicates
the clinical application of LXR agonists [20,21]. The underlying
molecular mechanisms inducing these adaptations in lipid and
sterol metabolism are not fully understood. An extensive data set
of C57BL/6J mice treated with T0901317 for 0, 1, 2, 4, 7, 14, and
21 days was generated and included in the computational analysis.
A remarkable prediction was obtained concerning the scavenger
receptor class B1 (SR-B1), a receptor that facilitates the uptake of
cholesterol from high-density-lipoproteins (HDL) by the liver. As
LXR agonists promote cholesterol efflux from peripheral cells and
excretion of cholesterol from the body, it was expected that hepatic
SR-B1 expression would be induced upon treatment to accom-
modate the increased hepatobiliary cholesterol excretion. Howev-
er, the computational analysis showed that the SR-B1 expression
decreased rather than increased upon T0901317 treatment. We
recently confirmed this counter-intuitive prediction experimentally
by immunoblot analysis of SR-B1 protein expression in hepatic
membranes [27]. Results from the computational analysis
provided an integrative understanding of the dynamic response
induced by T0901317 treatment that was not directly apparent
from the experimental data itself. For instance, the results show a
clear distinction between the processes that had an early onset and
were rapidly activated, and processes that changed progressively
during the treatment period.
Methods
In the following sections we present a step-by-step generic
description of the methodology underlying ADAPT. The ap-
proach consists of several steps which are discussed below and
schematically depicted in Figure 1. A more in-depth illustration of
how the time-varying parameters are estimated is provided in
Figure 2.
Ethics statement
A detailed description of the experimental materials and
procedures is available (see Supporting Information Text S1).
Experimental procedures were approved by the Ethics Committee
for Animal Experiments of the University of Groningen.
Experimental data and Monte Carlo sampling of
interpolants
Quantitative experimental data at different stages of a treatment
intervention are required to study the dynamics of induced
molecular adaptations. In metabolic research the acquired
Author Summary
A driving ambition of medical systems biology is to
advance our understanding of molecular processes that
drive the progression of complex diseases such as Type 2
Diabetes and cardiovascular disease. This insight is
essential to enable the development of therapies to
effectively treat diseases. A challenging task is to investi-
gate the long-term effects of a treatment, in order to
establish its applicability and to identify potential side
effects. As such, there is a growing need for novel
approaches to support this research. Here, we present a
new computational approach to identify treatment effects.
We make use of a computational model of the biological
system. The model is used to describe the experimental
data obtained during different stages of the treatment. To
incorporate the long-term/progressive adaptations in the
system, induced by changes in gene and protein expres-
sion, the model is iteratively updated. The approach was
employed to identify metabolic adaptations induced by a
potential anti-atherosclerotic and anti-diabetic drug target.
Our approach identifies the molecular events that should
be studied in more detail to establish the mechanistic basis
of treatment outcome. New biological insight was
obtained concerning the metabolism of cholesterol, which
was in turn experimentally validated.
Trajectory Analysis to Identify Treatment Effects
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Figure 1. Computational workflow of ADAPT to analyze the effects of a treatment intervention. Step 1. Quantitative experimental data
was generated at different stages of a treatment intervention. Step 2. Cubic smoothing splines were calculated that describe the dynamic trend of the
experimental data. To account for experimental and biological uncertainties a collection of splines was calculated using a Monte Carlo approach. Step
3. The cubic splines were used as input for the computational approach to iteratively estimate dynamic trajectories of metabolic parameters and
fluxes. The additional insights obtained via the computational analysis could be used to design new experiments, and repeat the mentioned steps.
For each step an example is given. The data is represented by means + standard deviations.
doi:10.1371/journal.pcbi.1003166.g001
Trajectory Analysis to Identify Treatment Effects
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experimental data typically provides information about changes
in metabolite concentrations in plasma and tissue compartments
[28–31] (Figure 1, step 1). In the present study mathematical
modeling is employed to generate additional insight on the
treatment response by predicting which metabolic parameters
and consequently metabolic fluxes necessarily have to change to
describe the dynamic trend in the experimental data. The
metabolic parameters and fluxes can generally not be considered
constant in time. Due to the treatment intervention these
quantities typically change in a time-dependent fashion. To
allow for estimation of dynamic trajectories of metabolic
parameters and fluxes, continuous dynamic descriptions of the
experimental data were used as input for ADAPT. For this
purpose, cubic smoothing splines were calculated that describe
the dynamic trend of the experimental data (Figure 1, step 2). To
account for experimental and biological uncertainties a collection
of splines was calculated using a Monte Carlo approach.
Different random samples of the experimental data were
generated assuming Gaussian distributions with means and
standard deviations of the data. Subsequently, for each generated
sample a cubic smoothing spline was calculated.
Mathematical modeling to describe the underlying
biological system
Fundamental in ADAPT is the development of a computational
model that includes mathematical descriptions of the molecular
pathways of interest. The present study focused on biological





Figure 2. Estimation of time-dependent parameters. The progression of adaptations induced by a treatment intervention is predicted by
identifying necessary dynamic changes in the model parameters to describe the transition between experimental data obtained during different
stages of the treatment. The time-dependency of the parameters is introduced by dividing a simulation in Nt steps of Dt time period. Initially (n~0)
the system is in steady-state and corresponding parameters ~h½0 are estimated to describe the experimental data of the untreated phenotype.
Subsequently, for each step nw0 the system is simulated for a time period of Dt using the final values of the model states of the previous step
~X ½n{1 as initial conditions (B). Simultaneously, parameters~h½n are estimated (A) by minimizing the difference between the data interpolants and
corresponding model outputs ~Y ½n (C). Here, the previously estimated parameter set ~h½n{1 was provided as initial set for the optimization
algorithm.
doi:10.1371/journal.pcbi.1003166.g002
Trajectory Analysis to Identify Treatment Effects
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where _~x is a vector of first derivatives of molecular species (or
states)~x which are given by the topology of the network, matrix N,
and a set of functions ~f . The initial concentrations of ~x are given
by ~x0. The vector~y represents the model outputs, which are given
by a set of functions ~g including mathematical expressions that
map the model states to specific quantities of interest. Both
functions ~f and ~g depend on kinetic parameters ~h and optional
inputs ~u.
Parameterization of the untreated phenotype
In ADAPT the mathematical model is first used to describe
the untreated phenotype (t~0). It was assumed that prior to the
onset of a treatment intervention the concentrations and fluxes
in the biological system were in steady-state. The following
protocol was employed to capture multiple parameter sets
describing the untreated phenotype. The weighted sum of
squared errors between the experimental data of the untreated










where Ny is the number of measurement signals, ~yss the steady-
state model outputs, ~d the interpolant functions describing the
experimental data and ~s corresponding standard deviations
(which are here evaluated at t~0). The parameters were






where ~^h0 represents the optimized parameter set for the
untreated phenotype. A Monte Carlo approach was employed
to account for methodological and experimental uncertainties.
First, the optimization procedure was repeated for a widely
dispersed range of initial parameter values (10{6 to 106).
Secondly, in each optimization a different spline function for ~d
was used. Finally, a collection of N0 parameter sets is obtained
denoted by H^0 that describe the untreated phenotype:
H^0~ ~^h0,1,~^h0,2,    ,~^h0,N0
n o
ð6Þ
These parameter sets will serve as a starting point from which
necessary dynamic changes are identified to describe the
transition between experimental data obtained during different
stages of the treatment.
Time-dependent descriptions of model parameters
In many cases insufficient information is available to define the
essential interaction mechanisms which are modulated by a
specific treatment intervention, let alone to generate explicit
mathematical descriptions of these processes. As a consequence,
the dynamic adaptations in molecular processes were captured by
inferring necessary changes in the model parameters which are
therefore time-dependent. Note that it is not known a priori how
the model parameters change during the experiment. Conse-
quently, it is not possible to perform a dynamic simulation of the
entire experiment in one go. This issue was addressed by dividing
the simulation of the system in Nt steps of Dt time period using the
following discretization (Figure 2):
~X ½n~~x(Dt,~h½n) with ~x(0)~~X ½n{1 ð7Þ
~Y ½n~~g(~X ½n,~h½n,~u) ð8Þ
~X ½0~~xss(~h½0), ~h½0[H^0 ð9Þ
where ~X and ~Y are the discretized quantities of ~x and ~y
respectively, and 0ƒnƒNt with NtDt the time period of the entire
experiment. The simulation is initiated (n~0) using the steady-
state values of the model states ~xss obtained with parameter set
~h½0, which is part of the collection H^0 that describes the untreated
phenotype. Subsequently, for each step nw0 the system is
simulated for a time period of Dt using the final values of the
model states of the previous step n{1 as initial conditions. Note
that the model parameters are time-dependent and that each step
the system is simulated with a different parameter set. Parameters
~h½n were estimated by minimizing the difference between
experimental data (corresponding data interpolant) and corre-
sponding model outputs ~Y ½n. Here, the previously estimated
parameter set ~h½n{1 was provided as initial set for the
optimization algorithm. It was assumed that the induced
adaptations proceed progressively in time. Therefore, highly
fluctuating parameter trajectories were considered to be unphys-
iological. To prevent the occurrence of such behavior, a
regularization term, given by the sum of squared derivatives of
the normalized parameter values at current step n, was included in
the parameter estimation procedure. An optimized parameter set,





where x2d represents the objective function that minimizes the sum
of squared differences between the data interpolants and model
outputs, and x2r represents the regularization objective function.






















where Np is the number of parameters, and lr a constant
determining the strength of the regularization term. A minimal
value for lr was chosen to bias the data fitting as little as possible
[1]. Note that x2r effectuates that changing a parameter is costly,
which will therefore be avoided if this is not required to describe
the experimental data. Relative derivatives were used to assign
equal relevance to all parameters and to avoid domination of the
optimization by large absolute values. Finally, trajectories of the
parameters (and consequently also for the model states and fluxes)
are obtained that describe the transition of the phenotype during
the treatment intervention. By repeating the optimization proce-
Trajectory Analysis to Identify Treatment Effects
PLOS Computational Biology | www.ploscompbiol.org 5 August 2013 | Volume 9 | Issue 8 | e1003166
dure for all initial parameter sets in collection H^0 a distribution of
trajectories is obtained (Figure 1, step 3).
Time-dependent sensitivities of trajectories
The calculated trajectories of molecular states, parameters and
fluxes can be used for a wide range of analysis techniques to study
the induced molecular adaptations. A class of computational
techniques that is frequently applied to systems biology models
(and complex systems in general) is sensitivity analysis [32–35].
One such method is the multi parametric sensitivity analysis
(MPSA), which is frequently used to study the relative importance
of parameters with respect to model outputs. MPSA is a global
sensitivity method that was first proposed in the field of hydrology
[36]. More recently, the method was also applied to study
biological systems [33,35,37,38]. An advantage of the MPSA
method is that it allows to detect combinatorial effects of
parameters on model outputs (by varying all parameters simulta-
neously) that might go unnoticed in local parameter sensitivity
analysis based methods (see Supporting Information Text S2 for
an example). Here, we briefly discuss the methodology and
illustrate how this technique can be applied within the framework
of ADAPT. Consider a parameter v and a model output of interest
w. The basic principle of MPSA is to propagate the uncertainty of
v into w by sampling parameter sets from predefined distributions
and evaluate corresponding outcomes of the model output. For the
present case these distributions are given by the outcomes of the
trajectories corresponding to v and w at a specific time step n. The
samples of v are subsequently classified as acceptable or
unacceptable by comparing corresponding outputs w (or some
metric involving w) with a threshold. A threshold that is typically
used, which was used here as well, is the mean of w [33,35,37,38].
Next, the samples are sorted according to parameter v and
cumulative distributions of the acceptable (Sa) and unacceptable















with pa and pu given by:















where ~V ½n and ~W ½n are vectors (sorted according to parameter v)
of length Ns containing the samples of v and w respectively at time
step n. The supremum of the difference between these distribu-




where KS represents the Kolmogorov-Smirnov distance. The KS
distance serves as a sensitivity metric indicating how strongly
acceptance and nonacceptance correlate to parameter v, i.e., how
sensitive the output w is with respect to the uncertainty in
parameter v. Note that the KS distance is bounded between zero
and one, where a higher value indicates a relatively higher
importance of the parameter variation to the model output. A
critical value for KS was obtained from the Kolmogorov
distribution using a significance level of 0:05 [39,40]. Another
remark is that v can be any quantity expressed in the mathematical
model and is not restricted to parameters. The KS distance was
calculated for each time step to study the time-dependency of
model sensitivities.
Results
In the present section ADAPT is applied to identify which
metabolic adaptations are induced upon pharmacological treat-
ment of mice with LXR agonist T0901317 up to three weeks. The
perturbation by means of this treatment starts at the proteome
level and subsequently induces adaptations at the other levels
(Figure 3, left part). Mathematical modeling was focused on
integrating pathways from the metabolome level, as the network
topology is relatively well known and the majority of the
experimental data was derived from this level (Figure 3, right
part). The modulating effects on metabolic pathways via
interactions with the proteome and transcriptome levels were
captured by time-dependent descriptions of the parameters.
Pharmacological treatment of LXR using agonist
T0901317
An extensive data set of C57BL/6J mice treated with T0901317
for 0, 1, 2, 4, 7, 14, and 21 days was generated and included in the
computational analysis. A detailed description of the experimental
materials and procedures is available (see Supporting Information
Text S1). In brief, the set contains quantitative measures of hepatic
triglyceride, free cholesterol, and cholesterylester levels, as well as
the fractional contribution of de novo lipogenesis to the hepatic
triglyceride pool. Furthermore, data on plasma concentrations of
triglyceride, total cholesterol, HDL-cholesterol, and free fatty acids
(FFA) were included. We also included data on VLDL production,
VLDL clearance, VLDL particle size, and VLDL composition.
Quantitative data on hepatic cholesterol uptake in untreated mice
was derived from [41].
Computational framework
A mathematical multi-compartment model of mouse hepatic
lipid and plasma lipoprotein metabolism was used to predict the
dynamics of metabolic adaptations induced upon pharmacological
activation of LXR [1]. In the present study several small
modifications were made to this model. In brief, the mathematical
model contains three compartments representing the liver, blood
plasma, and peripheral tissues. The liver includes the production,
utilization and storage of triglycerides and cholesterols, as well as
the mobilization of these metabolites to the endoplasmic reticulum
where they are incorporated into nascent produced VLDL
particles. These VLDL particles are subsequently secreted in the
plasma compartment and provide nutrients for peripheral tissues.
The model furthermore includes the hepatic uptake of free fatty
acids from the plasma that predominantly originate from adipose
Trajectory Analysis to Identify Treatment Effects
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tissue. Finally, the model includes the reverse cholesterol transport
pathway, i.e., the net transport of cholesterol from peripheral
tissues back to the liver via HDL. A detailed description of the
mathematical model, including equations, is available (see
Supporting Information Text S3).
The rationale for including the aforementioned biological
processes in the mathematical model is to generate a close and
balanced match between model complexity and the available
experimental data. The level of detail at which certain biological
processes can be integrated in a mathematical model is determined
by the selection of molecular species, as well as the type and
quality of the measurements. Therefore, the model size and
complexity of the reaction equations was kept to a minimum.
Furthermore, model development was focused on integrating
biological pathways from which the topology is well known and a
substantial amount of components were measured quantitatively,
i.e. mass fluxes at the metabolome level. The network topology of
metabolic pathways is relatively well known and is available for
different organisms in various pathway databases such as listed in
Pathguide (http://www.pathguide.org). The modulating and
regulatory effects on metabolic pathways via interactions with
the proteome and transcriptome levels are less well understood. At
present it is not yet feasible to include a full mechanistic
description of these interactions in the model. Note that the
computational model does not include any mathematical descrip-
tions of processes involved in LXR activation and its transcrip-
tional response. ADAPT overcomes the problem of undermodel-
ing by introducing time-dependent parameters that account for
the missing interactions.
Analysis of the cascade of induced molecular adaptations
The computational workflow of ADAPT was carried out using
the computational model and the acquired experimental data. An
overview of the experimental data and corresponding spline
interpolants that were used as input for ADAPT is presented in
Supporting Information Text S4. Parameter trajectories were
estimated using 200 time steps. The impact of changing the
number of time steps on the model outputs was investigated (see
Supporting Information Text S5). A small value of 0:01 for
regularization factor lr was chosen to bias the data fitting as little
as possible (see Supporting Information Text S6). A collection of
10000 acceptable parameter trajectory sets was obtained
describing the experimental data. The dynamic characteristics
of the resulting state, parameter, and flux trajectories were
investigated to study the cascade of induced molecular adapta-
tions. For this purpose, the rise and fall periods of the trajectories
were calculated [42,43], which provides a broad overview of the
response dynamics. The rise period is defined as the time period
during which a trajectory rises from 10% to 90% of its maximal
value or between two extrema. Similarly, the fall period is defined
as the time period during which a trajectory falls from 90% to
10% of its maximal value or between two extrema. Figure 4
shows a selection of the rise and fall periods of metabolic
concentrations, parameters, and fluxes, clustered by four major
metabolic pathways: HDL metabolism, VLDL metabolism,
hepatic triglyceride metabolism, and hepatic cholesterol metab-
olism. The rise and fall periods are respectively represented by
light-gray and dark-gray bars (median + median absolute
deviation). A few observations can be made. First, there is a
clear distinction between processes that have an early onset and
were rapidly activated, and those that changed progressively
during the treatment period. This is of importance as the latter
processes likely play a crucial role in the long-term effects of the
pharmacological intervention. Secondly, the majority of the
processes were up-regulated in time. Interestingly, only a small
collection of processes included in the model was down-regulated
in time compared to the untreated phenotype. Two of these
processes, the secretion of VLDL particles and the hepatic HDL-
C uptake capacity, were explored in more detail as outlined in the
following sections.
Figure 3. Application of ADAPT to identify adaptations upon pharmacological treatment of mice by LXR agonist T0901317. The
intervention starts at the proteome level and subsequently induces adaptations at the other levels (left part, vertical arrows). Mathematical modeling
was focused on integrating biological pathways from which the topology is well known and a substantial amount of components were measured
quantitatively, i.e. the metabolome level (right part). A detailed description of the mathematical model is presented in Supporting Information Text
S3. The modulating effects on metabolic pathways via interactions with the proteome and transcriptome levels are less well understood. At present it
is not yet feasible to include a full mechanistic description of these interactions in the model. ADAPT overcomes this problem by introducing time-
dependent parameters that incorporate missing modulating effects.
doi:10.1371/journal.pcbi.1003166.g003
Trajectory Analysis to Identify Treatment Effects
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The rate of VLDL particle secretion is reduced upon LXR
activation
The estimated trajectories representing the dynamic behavior of
the hepatic secretion of VLDL particles to the plasma were
investigated. To this end 2D histograms were calculated to
determine the density of trajectories during the treatment period
(Figure 5). A darker color represents a higher density of trajectories
in that specific region and time point. The white lines enclose the
central 67% of the densities. It can be observed that the VLDL
particle secretion decreased rapidly up to one week of treatment
and subsequently stabilized upon prolonged treatment (Figure 5a).
Although the secretion of VLDL particles decreased, an increased
release of VLDL-TG to the plasma was experimentally observed
(Figure 5b). Similarly, the computational analysis showed an
increased production of VLDL-CE to the plasma (Figure 5c).
According to the model the progressive increase of these fluxes was
facilitated by an increased loading of triglycerides and cholesterol
onto VLDL particles (Figure 5d,e).
The hepatic HDL-C uptake capacity is reduced upon LXR
activation
Fast protein liquid chromatography (FPLC) measurements from
pooled mice plasma showed an increased level of HDL-C (&2 fold
increase) after one week of treatment, which remained at this
elevated level upon prolonged treatment (Figure 6a). Analysis of
the parameter and flux trajectory densities revealed that the rise in
HDL-C was initiated by a progressive increment of cholesterol
efflux from peripheral cells to HDL particles during the first week
of treatment (Figure 6b). This increased efflux was accompanied
by an elevated hepatic HDL-C uptake (Figure 6c). Interestingly,
only a minor difference between the efflux and uptake rates of
HDL-C (&4%) could be observed during the first week of
treatment (Figure 6d), implicating that only a small net effect in
HDL-C metabolism underlies the marked increase in circulating
HDL-C levels (Figure 6a). Although the hepatic uptake of HDL-C
was increased, the computational analysis showed that the hepatic
HDL-C clearance capacity was reduced upon treatment
(Figure 6e). Here, clearance capacity is defined as the ability to
clear a certain amount of substrate per time unit from the plasma,
which depends on the receptor number and corresponding activity
level. The scavenger receptor class B1 (SR-B1) contributes to the
hepatic uptake of cholesterol. Recently, we experimentally
confirmed that the SR-B1 protein level is reduced in hepatic
membranes upon T0901317 treatment (Figure 6e) [27]. Of note,
this data serves as an independent validation which was not
included in the optimization procedure.
Analysis and targeting of unwanted side effects
Besides its beneficial effects on cholesterol metabolism, phar-
macological LXR activation also induces unwanted side effects
such as the accumulation of triglycerides in the liver. A sensitivity
analysis was performed to investigate to which adapting processes
the hepatic triglyceride level is sensitive, and therefore potentially
played a role in the excessive accumulation of triglycerides in the
liver. The quantity of interest w is given by the total hepatic
triglyceride pool (x4zx5zx6zx7). Figure 7 presents the mean
KS distances for all states, parameters, and fluxes. To assess the
consistency of the KS distances, one hundred batches were
generated, each containing thousand randomly selected optimized
trajectories. Subsequently, the temporal sensitivities were calcu-
lated for each batch, providing a measure of the uncertainty
associated with the calculated profiles. Changing the number of
batches did not qualitatively change the profiles. A KS distance
was considered significant when it exceeds the critical value
indicated by the dotted lines (obtained from the Kolmogorov
distribution using a significance level of 0:05). The hepatic
triglyceride level was found to be sensitive to adaptations in only
a small subset of the model quantities. Three examples of dynamic
sensitivity profiles are presented (Figure 7, bottom). With respect to
the metabolic states, the total hepatic triglyceride level is sensitive
with respect to adaptations in the cytoplasmic triglyceride pool (x4
and x6) as expected. However, note that the total hepatic
triglyceride level is merely negligible sensitive to adaptations in
endoplasmic reticulum triglyceride pool (x5 and x7). The analysis
furthermore shows that the total hepatic triglyceride level is
sensitive to changes in the triglyceride catabolism capacity, as well
as the transport capacity/fluxes of triglyceride from the cytoplasm
to the endoplasmic reticulum. Note that the sensitivity profiles are
not static but change during the treatment period, implying that
the response of w induced by perturbation of v will vary between
different stages of the treatment.
The processes to which the hepatic triglyceride level is sensitive
are potential targets for future interventions to prevent the
unwanted side effect of excessive triglyceride accumulation in
the liver. To illustrate this, we performed a computational analysis
to investigate whether it is possible to prevent hepatic triglyceride
accumulation upon T0901317 treatment by targeting one of the
sensitive quantities, i.e., the triglyceride catabolism capacity (p8).
Here, triglyceride catabolism is defined as the hydrolysis of
triglyceride into fatty acids and glycerol which are subsequently
used in processes such as b-oxidation, gluconeogenesis, ketogen-
esis, sterol- and phospholipid synthesis. The 10000 parameter
trajectory sets obtained from the previous analysis were used as
input to simulate the computational model, with an exception for
p8. This parameter is iteratively re-estimated (while keeping the
other parameters fixed according to their trajectories) to maintain
a constant hepatic triglyceride level (x4zx5zx6zx7) during the
treatment intervention. The results of this analysis are depicted in
Figure 8. The previous computational analysis showed that the
triglyceride catabolism capacity was reduced upon treatment (top
left), which is partly responsible for the hepatic triglyceride
accumulation (top right). Re-estimation of parameter p8, while
forcing the total hepatic triglyceride pool to remain constant in
time (bottom right), indicates that this objective could be achieved
by designing an intervention that maintains the triglyceride
catabolism capacity at the level of untreated mice (bottom left).
Furthermore, applying this perturbation induced only negligible
adaptations in the other metabolite concentrations (see Supporting
Information Text S7). Another possibility is to target the
triglyceride transport from the cytoplasm to the endoplasmic
reticulum (f11 and p11). Although targeting p11 also provides a
successful strategy to prevent hepatic triglyceride accumulation, it
induces another unwanted side effect, i.e., the accumulation of
triglycerides in the plasma (see Supporting Information Text S7).
Discussion
A relevant topic explored in medical systems biology is the
development of computational models and techniques to study the
effectiveness of pharmacological interventions to treat progressive
diseases. We presented ADAPT, a new modeling approach to
analyze the long-term effects of a pharmacological intervention,
which is particularly useful to study adaptations in metabolic
pathways.
Pharmacological interventions are usually very complex in the
sense that they affect multiple processes operating at different
levels (metabolome, proteome, and transcriptome) and different
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Figure 4. Rise and fall periods of metabolic concentrations, parameters, and fluxes. The rise and fall periods are represented by light-gray
and dark-gray bars (median+ median absolute deviation), respectively. The rise period is defined as the time period during which a trajectory rises
from 10% to 90% of its maximal value. Similarly, the fall period is defined as the time period during which a trajectory falls from 90% to 10% of its
maximal value.
doi:10.1371/journal.pcbi.1003166.g004
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Figure 5. The VLDL particle secretion is reduced upon LXR activation. 2D histograms were calculated from the 10000 acceptable sets to
determine the density of trajectories during the treatment period. A darker color represents a higher density of trajectories in that specific region and
time point. The white lines enclose the central 67% of the densities. A) VLDL particle secretion. B) VLDL-TG production. The data is represented by
mean + standard deviation. C) VLDL-CE production. D) Ratio of VLDL-TG production to VLDL particle secretion. E) Ratio of VLDL-CE production to
VLDL particle secretion.
doi:10.1371/journal.pcbi.1003166.g005
Figure 6. The hepatic HDL-C uptake capacity is reduced upon LXR activation. 2D histograms were calculated from the 10000 acceptable
sets to determine the density of trajectories during the treatment period. A darker color represents a higher density of trajectories in that specific
region and time point. The white lines enclose the central 67% of the densities. A) HDL-C concentration. The white dots represent the experimental
data obtained via FPLC measurements from pooled mice plasma. B) Peripheral cholesterol efflux to HDL particles. C) Hepatic uptake of HDL-C. D)
Difference between peripheral cholesterol efflux to HDL and HDL-C uptake by the liver. E) Normalized hepatic uptake capacity of HDL-C, which is
assumed to be proportional the SR-B1 protein level. This prediction was recently confirmed experimentally by immunoblotting measurements of SR-
B1 in hepatic membranes [27] (data represent means+ standard deviations). Note that this data serves as an independent validation and was not
included in the optimization procedure.
doi:10.1371/journal.pcbi.1003166.g006
Trajectory Analysis to Identify Treatment Effects
PLOS Computational Biology | www.ploscompbiol.org 10 August 2013 | Volume 9 | Issue 8 | e1003166
timescales. Therefore, in many cases insufficient information is
available to define the essential interaction mechanisms which are
modulated by a specific treatment intervention. Hence including a
full mechanistic description of these interactions in a mathematical
model is not possible. ADAPT provides a solution to overcome the
problem of undermodeling by introducing time-dependent
parameters that account for the missing interactions. We have
previously reported a concept of varying parameters [1]. In this
study parameter differences/adaptations were estimated to iden-
tify molecular differences between phenotypes. The approach was
developed to study steady-state differences in concentrations and
fluxes between experimentally observed phenotypes. In contrast to
ADAPT, no notion of time is integrated in the approach and the
dynamics between phenotype transitions were not considered.
ADAPT aims to dynamically link different experimentally
observed phenotypes (phenotype snapshots) as a function of time,
hereby providing an integrated understanding of the outcome of a
pharmacological intervention or disease progression.
A concept of time-varying parameters is also used in linear
parametric-varying (LPV) control analysis. LPV systems are
predominantly applied to design gain-scheduled multivariate
controllers [44,45]. LPV systems are developed for different
purposes and there are several essential differences compared to
ADAPT. First, LPV controllers are restricted to linear systems.
Second, LPV control analysis requires the time variation of
parameters to be measured in real-time. The field of Systems
Biology deals with the opposite challenge however. In case of
biological systems the time variation in parameters is typically not
known, and it is therefore the objective of ADAPT to estimate
these. Linear time-varying (LTV) systems represent another class
of systems in control theory that bear similarities with ADAPT. In
LVT systems the input-output characteristics vary with time.
These systems are used to design adaptive observers and
controllers [46,47]. These methods also presume that the
mechanisms causing the time-dependent differences in output
behavior are known or can be measured.
To allow for time-dependent optimization of model parameters
according to equation (10) at any time point during a treatment
intervention, experimental data at that specific time point is
needed. Therefore, continuous dynamic descriptions of the
experimental data are required. This issue was addressed by
calculating data interpolants. The selection of an appropriate
interpolation scheme is important as it determines the dynamic
behavior of corresponding model quantities. Considering the
uncertainty associated with the acquired experimental data, it was
decided to use cubic smoothing splines to describe the experi-
mental data. These descriptions are preferred in cases of noisy
observations [48]. Note that the usage of splines provides the
Figure 7. Sensitivity analysis of the hepatic triglyceride accumulation. A sensitivity analysis was performed to identify adapting processes
for which the hepatic triglyceride level is sensitive. The quantity of interest w is given by the total hepatic triglyceride pool (x4zx5zx6zx7). A
hundred batches, each containing thousand randomly selected optimized trajectories, were generated. Subsequently, for each batch the temporal
sensitivities were calculated. Top) mean KS distances for all states, parameters, and fluxes. Bottom) Three examples of dynamic sensitivity profiles. A
KS distance was considered significant when it exceeds the critical value indicated by the dotted lines (obtained from the Kolmogorov distribution
using a significance level of 0:05).
doi:10.1371/journal.pcbi.1003166.g007
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possibility to estimate the model parameters in a step-wise manner.
However, when considering ‘small’ models (low number of model
parameters Np) and/or a ‘low’ time resolution (low number of time
points Nt), such that the total number of parameters to be
estimated (Np|Nt) is relatively small, one could opt for an
approach to estimate all parameters in a single optimization
procedure. This approach is computationally expensive but could
provide a means to avoid the usage of data interpolants.
To account for variations in the dynamic behavior as well as
experimental and biological uncertainties, a collection of smooth-
ing splines was calculated using a Monte Carlo approach in which
random samples of the experimental data were generated. This
provides the possibility to determine the propagation of data
uncertainty through model predictions, and hence allows to
distinguish between predictions that are well constrained and as
such can be made confidently, and those that display a large
variation in possible outcomes. In case when parameter trajecto-
ries (or trajectories of states and fluxes) are not well-constrained by
the experimental data, it might be worthwhile to study relative
differences of these trajectories compared to the untreated
phenotype, which for several cases display consistent behavior
(see Supporting Information Text S8). The analysis of parameter
and prediction uncertainty is an important topic that triggered the
development of various methods [49–57]. The sampling of
replicates of experimental data and their subsequent utilization
in parameter estimation is a common approach to assess
prediction uncertainty, a class of methods also referred to as
bootstrapping [56,58–63]. Other approaches based on parameter
optimization have been proposed to assess the identifiability of
parameters [64] and predictions [50] or to probe consistent model
behavior (core predictions) among multiple parameter sets
[51,52,54,56]. Furthermore, Bayesian methods are available that
provide a probabilistic assessment of prediction uncertainty
[49,65–67]. A review of the state-of-the-art methods for uncer-
tainty analysis is presented in [68]. An additional analysis was
performed to investigate the identifiability of parameters for the
untreated phenotype, using ADAPT and the Profile Likelihood
method [64] (see Supporting Information Text S9).
ADAPT was applied to a model of hepatic lipid and plasma
lipoprotein metabolism to predict the metabolic adaptations
induced upon pharmacological treatment of mice with the LXR
agonist T0901317. As values for model parameters need to be
inferred from experimental data, mathematical modeling was
focused on integrating biological pathways from which a
substantial amount of components were measured quantitatively.
For the present case these predominantly concerned measure-
ments of metabolite concentrations in the liver and plasma.
Therefore, mathematical modeling was centered on integrating
corresponding pathways at the metabolic level. Interactions and
processes at the proteome and transcriptome levels were not
included, as insufficient information of the underlying network
structure and interaction mechanisms was available. Conversely,
Figure 8. Treatment design to prevent hepatic triglyceride accumulation. A computational analysis was performed to explore the
possibility to prevent hepatic triglyceride accumulation upon T0901317 treatment by targeting the triglyceride catabolism capacity (p8). The previous
computational analysis showed that the catabolism capacity decreased upon treatment (top left), which is partly responsible for the hepatic
triglyceride accumulation (top right). Re-estimation of parameter p8 , while forcing the total hepatic triglyceride pool to remain constant in time
(bottom right), indicates that this objective could be achieved by designing an intervention that maintains the untreated triglyceride catabolism
capacity (bottom left). The data is represented by means + standard deviations. The white lines enclose the central 67% of the densities.
doi:10.1371/journal.pcbi.1003166.g008
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these modulating effects were captured by inferring necessary
changes in the model parameters. Note that the computational
model does not include any mathematical descriptions of processes
involved in LXR activation and its transcriptional response. We
were able to quantitatively integrate data of untreated mice, as
well as mice treated with T0901317 up to three weeks into a
consistent model. The presented model predictions are in good
agreement with experimental observations and our previous
results [1]. An additional analysis was performed that confirms
that the parameters have to change in a time-dependent manner
to describe the experimental data. It was not possible to describe
the experimental data by simulating the system with time-constant
parameters or a step-wise response in the parameters (see
Supporting Information Text S10). The calculated trajectories of
metabolic states, parameters and fluxes can be used for a wide
range of analysis techniques to study the induced molecular
adaptations. Several of its potential applications were presented
here, e.g., sensitivity analysis, and therapy design.
The obtained trajectories provided the opportunity to study the
cascade of metabolic adaptations. Our results show a clear
distinction between processes that had an early onset and were
rapidly activated, and processes that changed progressively during
the treatment period. For instance, the peripheral uptake of
triglycerides via lipolytic enzymes is rapidly induced, while this
process is induced progressively in the liver (Figure 4, f22 vs. f23).
Analysis of the trajectories revealed that the majority of the processes
were up-regulated in time. Interestingly, only a small subset of the
included processes were down-regulated in time. One example
concerns the secretion of VLDL particles. The computational
analysis revealed that the secretion decreased rapidly up to one week
of treatment and subsequently stabilized upon prolonged treatment
(Figure 5a). This model prediction is consistent with the following
experimental observations. A reduced level of hepatic apolipoprotein
B mRNA (each VLDL particle contains one apolipoprotein B
protein) was observed in T0901317 treated mice [20,21,69].
Although the secretion of VLDL particles decreased upon
T0901317 treatment, the VLDL-mediated transport of triglycerides
and cholesterol to the plasma increased progressively (Figure 5b,c).
This was accomplished by an increased loading of these lipids onto
VLDL particles (Figure 5d,e), resulting in an enlargement of the
particle volume (see Supporting Information Text S4).
Model predictions furthermore indicated that the efflux of
cholesterol from peripheral tissues to HDL particles increased up
to one week of treatment (Figure 6b), which most likely resulted
from the induction of the cholesterol transporters ABCA1 and
ABCG1 in peripheral tissues. The increased cholesterol efflux was
closely followed by an increased uptake of HDL-C by the liver
(Figure 6c). However, a minor difference between the efflux and
uptake rates of HDL-C can be observed during the first week of
treatment (Figure 6d), resulting in an elevated plasma HDL-C level
(Figure 6a). Another interesting prediction obtained from the
computational analysis concerns SR-B1, a receptor that facilitates
the uptake of cholesterol from HDL by the liver. As LXR agonists
promote the efflux of cholesterol from the periphery and excretion
of cholesterol from the body, it was expected that SR-B1 expression
level would be induced upon treatment to accommodate the
increased hepatobiliary flux. In contrast, the computational analysis
showed that the hepatic capacity to clear HDL-C (assumed to be
proportional to the SR-B1 level) was reduced upon treatment
(Figure 6e). This counter-intuitive prediction was recently con-
firmed experimentally by immunoblotting analysis of SR-B1 protein
expression in hepatic membranes [27]. Hence, the increased HDL-
C concentration is not only a consequence of increased peripheral
cholesterol efflux to HDL particles [20,70] but also of impaired SR-
B1-mediated cholesterol uptake by the liver.
The calculated trajectories form a hypothesis on how the
various metabolic states, parameters, and fluxes changed during
the treatment intervention. These trajectories can subsequently be
exploited to establish the efficacy of a treatment and to identify its
potential side effects. In case unwanted side effects occur, the
trajectories may be used to design new or additional target
interventions to prevent these. Here, we presented an example
concerning the excessive accumulation of triglycerides in the liver
upon LXR activation. First, a sensitivity analysis was performed to
identify adapting processes to which the hepatic triglyceride level is
sensitive, and therefore potentially contributed to the accumula-
tion of triglycerides in the liver (Figure 7). Subsequently, we
performed a computational analysis to investigate the possibility to
maintain normal hepatic triglyceride levels upon T0901317
treatment by targeting the triglyceride catabolism capacity (p8),
one of the sensitive quantities. This parameter is iteratively re-
estimated to maintain a constant hepatic triglyceride content
during the treatment intervention, while keeping the other
parameters fixed according to their trajectories obtained from
the original analysis (Figure 8). Note that although all parameters
are fixed (with an exception for p8), the concentrations and fluxes
can change due to the targeting of p8. Here, we assumed that the
targeting of p8 induces merely negligible adaptations on the model
parameters. Figure 8 shows to what extent the catabolism capacity
should be targeted in order to maintain a hepatic triglyceride
content within the normal range. Such information can subse-
quently be used to design specific target interventions to achieve
this. One option could be to increase mitochondrial fatty acid
oxidation, thereby increasing triglyceride catabolism. Several
therapeutic strategies to achieve this have been proposed in recent
years [71–73]. Another strategy would be to inhibit Acetyl-CoA
carboxylase (ACC), the enzyme that catalyzes malonyl-CoA
synthesis. malonyl-CoA acts as an allosteric inhibitor of mito-
chondrial fatty acid oxidation. ACC inhibition will therefore
reduce malonyl-CoA levels, hence releasing the inhibitory effect
on fatty acid catabolism [74,75].
In conclusion, we presented ADAPT, a new modeling approach
to evaluate the consequences of a pharmacological intervention.
The calculated trajectories of metabolic states, parameters and
fluxes can be used for a wide range of analytical techniques to
study the molecular adaptations. They provide insight in the
affected underlying biological systems and identify the molecular
events that should be studied in more detail to unravel the
mechanistic basis of treatment outcome.
Supporting Information
Text S1 Description of the experimental procedures.
(PDF)
Text S2 An example of the multi parametric sensitivity analysis
(MPSA) method is demonstrated and compared with a local
sensitivity analysis method.
(PDF)
Text S3 Description of the mathematical model of hepatic lipid
and plasma lipoprotein metabolism, including an overview of the
states, parameters, fluxes, and ordinary differential equations.
(PDF)
Text S4 An overview of the experimental data and correspond-
ing spline interpolants that were used as input for ADAPT.
(PDF)
Trajectory Analysis to Identify Treatment Effects
PLOS Computational Biology | www.ploscompbiol.org 13 August 2013 | Volume 9 | Issue 8 | e1003166
Text S5 Analysis of the influence of changing the number of
time steps used in ADAPT on the model outputs and
regularization error.
(PDF)
Text S6 Analysis of the influence of changing the regularization
strength on the model outputs and regularization error.
(PDF)
Text S7 Analysis of unwanted side effects when targeting p8 or
p11 to prevent the excessive accumulation of triglycerides in the
liver upon T0901317 treatment.
(PDF)
Text S8 Analysis of relative adaptations of trajectories to identify
consistent model behavior.
(PDF)
Text S9 Analysis of the identifiability of parameters for the untr-
eated phenotype, using ADAPT and the Profile Likelihood method.
(PDF)
Text S10 Comparison of model outputs obtained with time-




We thank Barbara Bakker, Gijs den Besten, Theo van Dijk, and Karen van
Eunen for useful discussions.
Author Contributions
Conceived and designed the experiments: MHO AKG. Performed the
experiments: MHO. Wrote the paper: CAT. Developed the mathematical
model: CAT. Developed the computational approach: CAT. Developed
software to simulate compiled ODE. models in Matlab: JV. Analysed the
computational results: CAT JV MHO AKG PAJH NAWvR. Revised the
paper: JV MHO AKG PAJH NAWvR. Supervised the study: AKG PAJH
NAWvR.
References
1. Tiemann C, Vanlier J, Hilbers P, van Riel N (2011) Parameter adaptations
during phenotype transitions in progressive diseases. BMC Sys Biol 5: 174.
2. Fang X, Wallqvist A, Reifman J (2012) Modeling phenotypic metabolic
adaptations of mycobacterium tuberculosis h37rv under hypoxia. PLOS
Computational Biology 8: e1002688.
3. van Schalkwijk D, van Ommen B, Freidig A, van der Greef J, de Graaf A (2011)
Diagnostic markers based on a computational model of lipoprotein metabolism.
Journal of clinical bioinformatics 1: 1–16.
4. van Schalkwijk D, de Graaf A, van Ommen B, van Bochove K, Rensen P, et al.
(2009) Improved cholesterol phenotype analysis by a model relating lipoprotein
life cycle processes to particle size. Journal of lipid research 50: 2398–2411.
5. Fang X, Wallqvist A, Reifman J (2009) A systems biology framework for
modeling metabolic enzyme inhibition of Mycobacterium tuberculosis. BMC
Syst Biol 3: 92.
6. Young D, Stark J, Kirschner D (2008) Systems biology of persistent infection:
tuberculosis as a case study. Nat Rev Microbiol 6: 520–528.
7. Stefanini M, Wu F, Mac Gabhann F, Popel A (2008) A compartment model of
VEGF distribution in blood, healthy and diseased tissues. BMC Syst Biol 2: 77.
8. Wu X, Jiang R, Zhang M, Li S (2008) Network-based global inference of human
disease genes. Mol Syst Biol 4: 189.
9. Lusis A, Attie A, Reue K (2008) Metabolic syndrome: from epidemiology to
systems biology. Nat Rev Genet 9: 819–830.
10. Vanlier J, Tiemann C, Hilbers P, van Riel N (2012) A bayesian approach to
targeted experiment design. Bioinformatics 28: 1136–1142.
11. Hu P, Bader G, Wigle D, Emili A (2006) Computational prediction of cancer-
gene function. Nat Rev Cancer 7: 23–34.
12. Kitano H, Oda K, Kimura T, Matsuoka Y, Csete M, et al. (2004) Metabolic
syndrome and robustness tradeoffs. Diabetes 53: S6.
13. Csete M, Doyle J (2004) Bow ties, metabolism and disease. TRENDS in
Biotechnology 22: 446–450.
14. Schmitz J, Van Riel N, Nicolay K, Hilbers P, Jeneson J (2010) Silencing of
glycolysis in muscle: experimental observation and numerical analysis.
Experimental physiology 95: 380–397.
15. Schilling M, Maiwald T, Hengl S, Winter D, Kreutz C, et al. (2009) Theoretical
and experimental analysis links isoform-specific ERK signalling to cell fate
decisions. Mol Syst Biol 5: 334.
16. Borisov N, Aksamitiene E, Kiyatkin A, Legewie S, Berkhout J, et al. (2009)
Systems-level interactions between insulin–EGF networks amplify mitogenic
signaling. Mol Syst Biol 5: 256.
17. Cedersund G, Roll J, Ulfhielm E, Danielsson A, Tidefelt H, et al. (2008) Model-
based hypothesis testing of key mechanisms in initial phase of insulin signaling.
PLoS Comput Biol 4: 799–806.
18. Koschorreck M, Gilles E (2008) Mathematical modeling and analysis of insulin
clearance in vivo. BMC Syst Biol 2: 43.
19. Schoeberl B, Eichler-Jonsson C, Gilles E,Mu¨ller G (2002) Computational
modeling of the dynamics of the MAP kinase cascade activated by surface and
internalized EGF receptors. Nat Biotechnol 20: 370–375.
20. Grefhorst A, Elzinga B, Voshol P, Plo¨sch T, Kok T, et al. (2002) Stimulation of
lipogenesis by pharmacological activation of the liver X receptor leads to
production of large, triglyceride-rich very low density lipoprotein particles. J Biol
Chem 277: 34182–34190.
21. Grefhorst A, Parks E (2009) Reduced insulin-mediated inhibition of VLDL
secretion upon pharmacological activation of the liver X receptor in mice. J Lipid
Res 50: 1374–1383.
22. Ninness B, Goodwin GC (1995) Estimation of model quality. Automatica 31:
1771–1797.
23. Oosterveer M, Grefhorst A, Groen A, Kuipers F (2010) The liver X receptor:
Control of cellular lipid homeostasis and beyond: Implications for drug design.
Prog Lipid Res 49: 343–352.
24. Calkin A, Tontonoz P (2010) Liver X Receptor Signaling Pathways and
Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 30: 1513.
25. Joseph S, Castrillo A, Laffitte B, Mangelsdorf D, Tontonoz P (2003) Reciprocal
regulation of inflammation and lipid metabolism by liver X receptors. Nat med
9: 213–219.
26. Repa J, Mangelsdorf D (2002) The liver X receptor gene team: potential new
players in atherosclerosis. Nat med 8: 1243–1248.
27. Grefhorst A, Oosterveer M, Brufau G, Boesjes M, Kuipers F, et al. (2012)
Pharmacological lxr activation reduces presence of sr-b1 in liver membranes
contributing to lxr-mediated induction of hdl-cholesterol. Atherosclerosis 222:
382–9.
28. Biddinger SB, Hernandez-Ono A, Rask-Madsen C, Haas JT, Alema´n JO, et al.
(2008) Hepatic insulin resistance is sufficient to produce dyslipidemia and
susceptibility to atherosclerosis. Cell metabolism 7: 125–134.
29. Kalaany NY, Gauthier KC, Zavacki AM, Mammen P, Kitazume T, et al. (2005)
Lxrs regulate the balance between fat storage and oxidation. Cell metabolism 1:
231–244.
30. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, et al. (2004)
Effects of infection and inflammation on lipid and lipoprotein metabolism:
mechanisms and consequences to the host. The Journal of Lipid Research 45:
1169–1196.
31. Osono Y, Woollett L, Herz J, Dietschy J (1995) Role of the low density
lipoprotein receptor in the flux of cholesterol through the plasma and across the
tissues of the mouse. Journal of Clinical Investigation 95: 1124.
32. Marino S, Hogue I, Ray C, Kirschner D (2008) A methodology for performing
global uncertainty and sensitivity analysis in systems biology. Journal of
theoretical biology 254: 178–196.
33. Zi Z, Zheng Y, Rundell A, Klipp E (2008) Sbml-sat: a systems biology markup
language (sbml) based sensitivity analysis tool. BMC bioinformatics 9: 342.
34. van Riel N (2006) Dynamic modelling and analysis of biochemical networks:
mechanism-based models and model-based experiments. Briefings in Bioinfor-
matics 7: 364–374.
35. Zi Z, Cho K, Sung M, Xia X, Zheng J, et al. (2005) In silico identification of the
key components and steps in ifn-c induced jak-stat signaling pathway. FEBS
letters 579: 1101–1108.
36. Hornberger GM, Spear R (1981) Approach to the preliminary analysis of
environmental systems. J Environ Manage 12: 7–18.
37. Jeneson J, Schmitz J, van den Broek N, van Riel N, Hilbers P, et al.
(2009)Magnitude and control of mitochondrial sensitivity to adp. American
Journal of Physiology-Endocrinology And Metabolism 297: E774–E784.
38. Cho K, Shin S, Kolch W, Wolkenhauer O (2003) Experimental design in
systems biology, based on parameter sensitivity analysis using a monte carlo
method: A case study for the tnfa-mediated nf-k b signal transduction pathway.
Simulation 79: 726–739.
39. Wang J, Tsang WW, Marsaglia G (2003) Evaluating kolmogorov’s distribution.
Journal of Statistical Software 8: 1–4.
40. Pearson E, Hartley H (1958) Biometrika tables for statisticians. Cambridge:
Cambridge University Press, 240 pp.
41. Xie C, Turley S, Dietschy J (2009) Abca1 plays no role in the centripetal
movement of cholesterol from peripheral tissues to the liver and intestine in the
mouse. Journal of lipid research 50: 1316–1329.
42. Nise N (2007) Control systems engineering. New York: John Wiley & Sons, 880
pp.
Trajectory Analysis to Identify Treatment Effects
PLOS Computational Biology | www.ploscompbiol.org 14 August 2013 | Volume 9 | Issue 8 | e1003166
43. Levine W (1996) The control handbook. Boca Raton: CRC Press, 1548 pp.
44. Apkarian P, Gahinet P, Becker G (1995) Self-scheduled h1 control of linear
parameter-varying systems: a design example. Automatica 31: 1251–1261.
45. Bamieh B, Giarre L (2002) Identification of linear parameter varying models.
International Journal of Robust and Nonlinear Control 12: 841–853.
46. Zhang Q (2002) Adaptive observer for multiple-input-multiple-output (mimo)
linear time-varying systems. Automatic Control, IEEE Transactions on 47: 525–
529.
47. Tse E, Athans M (1970) Optimal minimal-order observer-estimators for discrete
linear time-varying systems. Automatic Control, IEEE Transactions on 15: 416–
426.
48. Craven P, Wahba G (1978) Smoothing noisy data with spline functions.
Numerische Mathematik 31: 377–403.
49. Vanlier J, Tiemann C, Hilbers P, van Riel N (2012) An integrated strategy for
prediction uncertainty analysis. Bioinformatics 28: 1130–1135.
50. Kreutz C, Raue A, Timmer J (2012) Likelihood based observability analysis and
confidence intervals for predictions of dynamic models. BMC Systems Biology 6:
120.
51. Cedersund G (2012) Conclusions via unique predictions obtained despite
unidentifiability–new definitions and a general method. FEBS Journal 279:
3513–3527.
52. Nyman E, Bra¨nnmark C, Palme´r R, Bruga˚rd J, Nystro¨m F, et al. (2011) A
hierarchical wholebody modeling approach elucidates the link between in vitro
insulin signaling and in vivo glucose homeostasis. Journal of Biological
Chemistry 286: 26028–26041.
53. Gomez-Cabrero D, Compte A, Tegner J (2011)Workflow for generating
competing hypothesis from models with parameter uncertainty. Interface Focus
1: 438–449.
54. Bra¨nnmark C, Palme´r R, Glad S, Cedersund G, Stra˚lfors P (2010) Mass and
information feedbacks through receptor endocytosis govern insulin signaling as
revealed using a parameter-free modeling framework. Journal of Biological
Chemistry 285: 20171–20179.
55. Hasenauer J, Waldherr S, Wagner K, Allgower F (2010) Parameter
identification, experimental design and model falsification for biological network
models using semidefinite programming. Systems Biology, IET 4: 119–130.
56. Cedersund G, Roll J (2009) Systems biology: model based evaluation and
comparison of potential explanations for given biological data. FEBS Journal
276: 903–922.
57. Gutenkunst R, Waterfall J, Casey F, Brown K, Myers C, et al. (2007) Universally
sloppy parameter sensitivities in systems biology models. PLoS Comput Biol 3:
1871–1878.
58. Kirk P, Stumpf M (2009) Gaussian process regression bootstrapping: exploring
the effects of uncertainty in time course data. Bioinformatics 25: 1300–1306.
59. Mu¨ller T, Faller D, Timmer J, Swameye I, Sandra O, et al. (2004) Tests for
cycling in a signaling pathway. Journal of the Royal Statistical Society:
Series C (Applied Statistics) 53: 557–568.
60. JoshiM, Seidel-Morgenstern A, Kremling A (2006) Exploiting the bootstrap
method for quantifying parameter confidence intervals in dynamical systems.
Metabolic engineering 8: 447–455.
61. DiCiccio T, Efron B (1996) Bootstrap confidence intervals. Statistical Science 11:
189–212.
62. DiCiccio T, Tibshirani R (1987) Bootstrap confidence intervals and bootstrap
approximations. Journal of the American Statistical Association 82: 163–170.
63. Efron B (1979) Bootstrap methods: another look at the jackknife. The annals of
Statistics 7: 1–26.
64. Raue A, Kreutz C, Maiwald T, Bachmann J, Schilling M, et al. (2009) Structural
and practical identifiability analysis of partially observed dynamical models by
exploiting the profile likelihood. Bioinformatics 25: 1923.
65. Girolami M, Calderhead B (2011) Riemann manifold langevin and hamiltonian
monte carlo methods. Journal of the Royal Statistical Society: Series B (Statistical
Methodology) 73: 123–214.
66. Toni T, Welch D, Strelkowa N, Ipsen A, Stumpf MP (2009) Approximate
bayesian computation scheme for parameter inference and model selection in
dynamical systems. Journal of the Royal Society Interface 6: 187–202.
67. Klinke D (2009) An empirical bayesian approach for model-based inference of
cellular signaling networks. BMC bioinformatics 10: 371.
68. Vanlier J, Tiemann C, Hilbers P, van Riel N (2013) Parameter uncertainty in
biochemical models described by ordinary differential equations. Mathematical
Biosciences [epub ahead of print] doi: 10.1016/j.mbs.2013.03.006.
69. Schultz J, Tu H, Luk A, Repa J, Medina J, et al. (2000) Role of LXRs in control
of lipogenesis. Genes Dev 14: 2831–2838.
70. PlLo¨sch T, Kok T, Bloks V, Smit M, Havinga R, et al. (2002) Increased
hepatobiliary and fecal cholesterol excretion upon activation of the liver x
receptor is independent of abca1. Journal of Biological Chemistry 277: 33870–
33877.
71. Thupari JN, Landree LE, Ronnett GV, Kuhajda FP (2002) C75 increases
peripheral energy utilization and fatty acid oxidation in diet-induced obesity.
Proceedings of the National Academy of Sciences 99: 9498–9502.
72. Frøyland L, Madsen L, Vaagenes H, Totland G, Auwerx J, et al. (1997)
Mitochondrion is the principal target for nutritional and pharmacological
control of triglyceride metabolism. Journal of lipid research 38: 1851–1858.
73. Reddy JK, Rao MS (2006) Lipid metabolism and liver inflammation. ii. fatty
liver disease and fatty acid oxidation. American Journal of Physiology-
Gastrointestinal and Liver Physiology 290: G852–G858.
74. Schreurs M, Kuipers F, Van Der Leij F (2010) Regulatory enzymes of
mitochondrial b-oxidation as targets for treatment of the metabolic syndrome.
obesity reviews 11: 380–388.
75. Thupari JN, Pinn ML, Kuhajda FP (2001) Fatty acid synthase inhibition in
human breast cancer cells leads to malonyl-coa-induced inhibition of fatty acid
oxidation and cytotoxicity. Biochemical and biophysical research communica-
tions 285: 217–223.
Trajectory Analysis to Identify Treatment Effects
PLOS Computational Biology | www.ploscompbiol.org 15 August 2013 | Volume 9 | Issue 8 | e1003166
